Renal Tumor Risk Higher in Lithium-Treated Patients

Share this content:
Lithium-Treated Patients at Increased Risk for Renal Tumors
Lithium-Treated Patients at Increased Risk for Renal Tumors

Lithium-treated patients are at increased risk of renal tumors, according to French researchers.

In a retrospective study of 170 lithium-treated patients, renal tumors developed in 14 (8.2%) over a 16-year period. These tumors included 7 malignant and 7 benign tumors. The mean duration of lithium exposure at diagnosis was 21.4 years. The cancers included 3 clear-cell and 2 papillary renal cell carcinomas, 1 hybrid tumor with chromophobe and oncocytoma characteristics, and 1 clear-cell carcinoma with leiomyomatous stroma. The benign tumors included 4 oncocytomas, 1 mixed epithelial and stromal tumor, and 2 angiomyolipomas.

RELATED: Renal Cell Carcinoma Resource Center

Lithium-treated patients had an incidence of renal tumors 7.5 times greater than that of the general French population, researchers reported in Kidney International (2014;86:184-190). Additionally, the researchers compared lithium-treated patients with chronic kidney disease (CKD) and a group of lithium-free CKD patients matched for age, sex, and estimated glomerular filtration rate. The frequency of renal cancer and oncocytoma was significantly higher in the lithium-treated group (4.1% vs. 0.3% and 2.4% vs. 0%, respectively).

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs